Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RANBP2
REST API REST API
Homo sapiens
RANBP2 is differentially expressed in 305 experiments: 120 organism parts: bone marrow, liver, ... (118 more);, 189 disease states: normal, prostate carcinoma, ... (187 more);, 100 cell types 396 cell lines 45 compound treatments and 72 other conditions.
Synonyms NUP358
Orthologs ENSGALG00000002590 (Gallus gallus)   ENSGALG00000001269 (Gallus gallus)   D4A054_RAT (Rattus norvegicus)   Ranbp2 (Mus musculus)   ENSGALG00000013985 (Gallus gallus)   YRB1 (Saccharomyces cerevisiae)   Nup358 (Drosophila melanogaster)   ranbp2 (Xenopus laevis)   ENSGALG00000006545 (Gallus gallus)   ENSCAFG00000001993 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, isomerase activity, M phase of mitotic cell cycle, protein binding, intracellular, mRNA transport, protein import into nucleus, mitotic cell cycle, protein folding, metal ion binding, mitotic prometaphase, intracellular transport, nucleus, carbohydrate metabolic process, peptidyl-prolyl cis-trans isomerase activity, nuclear pore, binding, transmembrane transport, Ran GTPase binding, protein transport, zinc ion binding, viral reproduction, glucose transport, regulation of glucose transport, protein sumoylation, hexose transport
InterPro Term PPIase_cyclophilin, Znf_RanBP2, TPR_2, RanBP, TPR-1, TPR_repeat, TPR-contain, IR1-M
UniProt Accession P49792, C9JRL5, D3DX73, E9PGT0, F8WBP7, F8WB60
Gene-Disease Assocation ENCEPHALOPATHY, ACUTE, INFECTION-INDUCED, 3, SUCEPTIBILITY TO; IIAE3
Search EB-eye ENSG00000153201
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-19397, E-GEOD-2450, ... (36 experiments)

Factor Value U/D Experiments
BT-474
2
E-GEOD-5823, E-GEOD-3529
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF-7
2
E-GEOD-19639, E-GEOD-20081
MDA468
2
E-MEXP-440, E-MTAB-62
SW480
2
E-MEXP-1014, E-MTAB-37
PC3
1
2
E-MEXP-2034, E-GEOD-14464, E-GEOD-5258
390 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, ... (52 experiments)

Factor Value U/D Experiments
fibroblast
3
E-GEOD-3920, E-GEOD-26672, E-GEOD-3204
mononuclear cell
2
E-GEOD-6053, E-GEOD-7307
stromal cell
1
2
E-MEXP-2034, E-GEOD-10797, E-MEXP-1327
partially reprogrammed human induced pluripotent stem cell
1
E-GEOD-18265
germ cell
1
E-MTAB-25
leydig cell
1
E-MTAB-25
94 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-12254, E-GEOD-16363, ... (65 experiments)

Factor Value U/D Experiments
prostate carcinoma
5
E-MTAB-62, E-MTAB-37, E-MEXP-2034, E-GEOD-7307, E-MEXP-1327 ... (5 experiments)
normal
12
15
E-GEOD-6338, E-GEOD-5370, E-GEOD-7307, E-TABM-666, E-GEOD-13501, ... (27 experiments)
gastric carcinoma
2
E-GEOD-15460, E-MTAB-37
retinoblastoma
2
E-MTAB-37, E-GEOD-96
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
colon carcinoma
2
E-MTAB-37, E-MTAB-62
183 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (29 experiments)

Factor Value U/D Experiments
dimethyl sulfoxide
2
E-GEOD-5824, E-GEOD-6932
none
3
4
E-GEOD-5824, E-TABM-868, E-GEOD-412, E-TABM-782, E-MEXP-1958, ... (7 experiments)
mannitol
1
E-GEOD-6400
interferon alpha
1
E-GEOD-1740
4OH-tamoxifen
1
E-GEOD-2292
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
39 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-22513, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-MEXP-2280, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MEXP-563 ... (5 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-21750, E-TABM-321, E-TABM-868, E-TABM-601, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-12773, E-TABM-127, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-MEXP-2069, E-TABM-15, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (8 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-33562, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor size
studied in E-GEOD-3494, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.368 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM